EGFR inhibitor versus chemotherapy as adjuvant treatment for locally-advanced EGFR-mutant non-small cell lung cancer

被引：0
|
作者：
Xie, P. [1 ]
Tang, W. [1 ]
Li, X. [1 ]
Dong, Y. [1 ]
Sun, X. [1 ]
Zhang, J. [2 ]
Yu, J. [1 ]
机构：
[1] Shandong Canc Hosp & Inst, Oncol, Jinan, Shandong, Peoples R China
[2] Linshu Peoples Hosp, Oncol, Linyi, Shandong, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1471P
引用
收藏
页码：597 / 598
页数：2
相关论文
共 50 条
  • [1] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ortega-Franco, Ana
    Rafee, Shereen
    [J]. ONCOLOGY AND THERAPY, 2022, 10 (01) : 13 - 22
  • [2] ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
    Ana Ortega-Franco
    Shereen Rafee
    [J]. Oncology and Therapy, 2022, 10 : 13 - 22
  • [3] Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
    Wiest, Nathaniel
    Majeed, Umair
    Seegobin, Karan
    Zhao, Yujie
    Lou, Yanyan
    Manochakian, Rami
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [4] Prognostic value of EGFR genotype in EGFR-mutant non-small cell lung cancer
    Syrigos, Konstantinos
    Kotteas, Ilias
    Paraskeva, Maria
    Gkiozos, Ioannis
    Boura, Paraskevi
    Tsagouli, Sofia
    Grapsa, Dimitra
    Charpidou, Andriani
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [5] Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small cell lung cancer patients
    Xiong, Liwen
    Lou, Yuqing
    Bai, Hao
    Li, Rong
    Xia, Jinjing
    Fang, Wentao
    Zhang, Jie
    Han-Zhang, Han
    Lizaso, Analyn
    Li, Bing
    Gu, Aiqin
    Han, Baohui
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2019,
  • [6] Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach
    Jassem, Jacek
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2019, 8 : S387 - S390
  • [7] Diffuse Lung Metastases in EGFR-Mutant Non-Small Cell Lung Cancer
    Digumarthy, Subba R.
    Mendoza, Dexter P.
    Padole, Atul
    Chen, Tianqi
    Peterson, P. Gabriel
    Piotrowska, Zofia
    Sequist, Lecia, V
    [J]. CANCERS, 2019, 11 (09)
  • [8] MET inhibitor capmatinib plus EGFR tyrosine kinase inhibitor nazartinib for EGFR-mutant non-small cell lung cancer
    Felip, E.
    Minotti, V.
    Soo, R.
    Wolf, J.
    Solomon, B.
    Tan, D. S. W.
    Ardizzoni, A.
    Lee, D. H.
    Sequist, L. V.
    Barlesi, F.
    Paz-Ares, L.
    Rodriguez-Abreu, D.
    Garcia Campelo, M. R.
    Sprauten, M.
    Djentuh, L. O'Sullivan
    Belli, R.
    Glaser, S.
    Zou, M.
    Giovannini, M.
    Yang, J. C-H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S829 - S830
  • [9] EGFR-mutant non-small cell lung cancer in Aberdeen, Scotland - Treatment and outcomes
    El-Shakankery, K.
    Steven, E.
    Clark, C.
    Stilwell, C.
    Kerr, K.
    Nicolson, M.
    [J]. LUNG CANCER, 2017, 103 : S35 - S36
  • [10] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
12345